HemaCare Corp. Signs Distribution Agreement With Korea-Based Partner
Seoul-based AccuResearch, Inc. to distribute HemaCare primary cells
LOS ANGELES--(BUSINESS WIRE)--HemaCare Corporation (OTCBB: HEMA), a leader in cell and tissue collection, processing, and cell therapy solutions, has expanded its global capabilities through a strategic distribution agreement in Korea with Seoul-based AccuResearch Korea, Inc. This partnership ensures researchers in South Korea can access HemaCare’s human healthy and disease state fresh and cryopreserved hematopoietic cell products for their basic scientific and cell therapy research and development needs in a timely manner and with local regional support.
“Our cell and tissue collection expertise, registry of highly profiled, recallable donors, extensive capabilities in cell processing, cold chain logistics management, and professional consulting services makes HemaCare a partner of choice to support the unique needs and requirements of worldwide scientific and cell therapy researchers”
HemaCare distribution agreements enable partners to actively provide support to local customers. A complete list of these distribution partners can be found at www.hemacare.com/distributors. International researchers are able to obtain both fresh and cryopreserved cells through direct shipments from HemaCare’s FDA-registered donor collection center, as well as its cell isolation laboratory in California, while receiving customer service and technical support in their native language through specially trained representatives locally in their region. HemaCare also provides ongoing technical training and marketing support to assist global partners in providing best in class service and support.
HemaCare is the recognized apheresis leader in supporting autologous and allogeneic cell therapy, as well as supplying a broad array of hematopoietic tissue-derived cells for research, including bone marrow and umbilical cord blood. What sets HemaCare apart from others is our heritage as a transfusable collection center with over 38 years of experience operating an FDA registered, cGMP/cGTP compliant donor center. HemaCare manages hundreds of reliable & recallable donors, who can meet various criteria for selection to be used for allogeneic cell therapy starting material globally.
According to Pete van der Wal, HemaCare’s Chief Executive Officer, HemaCare’s partnership through these regional agreements demonstrates the company’s commitment to supporting the global research and development of cell therapies.
“Our cell and tissue collection expertise, registry of highly profiled, recallable donors, extensive capabilities in cell processing, cold chain logistics management, and professional consulting services makes HemaCare a partner of choice to support the unique needs and requirements of worldwide scientific and cell therapy researchers,” van der Wal said.
Since 1978, HemaCare Bioresearch Products & Services has been the trusted research partner of choice from concept to commercialization. HemaCare is a leader in Cell and Tissue Collection, Processing and Cell Therapy, providing the high-quality biological material needed to ensure quality research outcomes that meet the unique needs of the scientific community. For more information please visit www.hemacare.com.
Lou Juliano, 631-521-9497